Study finds first-line biparametric MRI less cost-effective than PSA for prostate cancer screening

From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for prostate cancer screening, mainly due to false-positive results and overdiagnosis, according to a study published online June 4 in the Annals of Internal Medicine. Roman Gulati, from the Fred Hutchinson Cancer Center in Seattle, and colleagues examined the comparative effectiveness and cost-effectiveness of first-line bpMRI versus PSA-based screening in a decision analysis using a microsimulation model. The target population comprised U.S. men aged 55 years without prior screening or prostate cancer diagnosis. Read More

Related posts:

  1. Study finds just 18% of people who need lung cancer screening get it
  2. Study finds 1 in 12 patients labeled as having ‘benign’ results actually had high-risk prostate cancer
  3. Improving prostate cancer screening for transgender women
  4. Researchers tie higher county-level prostate cancer screening to better outcomes
  5. Medical costs are substantial and rising for privately-insured men with abnormal prostate cancer screening results
  6. AI better detects prostate cancer on MRI than radiologists, study shows
  7. Antibody-drug conjugate highly effective in preventing recurrence in early stage HER2+ breast cancer, trial finds
  8. Lung cancer screening found to prolong lives in real-world study

Leave a Reply

Your email address will not be published. Required fields are marked *